Biopharmaceuticals company Bristol Myers Squibb’s (NYSE:BMY) strong clinical and operational performance and continued momentum across its product portfolio helped it generate robust revenue growth in its last reported quarter. But given that its stock price has dipped recently, is now an opportune time to scoop up its shares? Read on.Global biopharmaceuticals company Bristol Myers Squibb (BMY) specializes in product development, licensing, and sale of biopharmaceutical products. Its product portfolio includes Opdivo for anti-cancer indications, Reblozyl for the treatment of anemia in adult patients with beta-thalassemia, and Revlimid, an oral immunomodulatory drug. BMY is headquartered in New York City.
Closing yesterday’s session at $60.15, the stock is trading 13.8% below the 52-week high of $69.75.
Though the stock’s price has dipped 13.1% over the past month, its impressive growth potential, significant clinical and regulatory milestones, and strategic collaborations with biopharmaceutical companies, including Pfizer , Inc. (NYSE:PFE), Otsuka Pharmaceutical Co., Ltd., and Bolt Biotherapeutics, Inc., are expected to boost its performance in the coming months. Furthermore, BMY’s robust product portfolio should help it achieve sustained growth.